Business Editors
MINNETONKA, Minn.--(BUSINESS WIRE)--Dec. 14, 2000--LecTec
Corporation (Nasdaq:LECT) LecTec Corporation proudly announces the
introduction of the tenth member of the innovative TheraPatch(R)
family of products - new TheraPatch Cold Sore(TM). In accordance with
our "FIRST PATCH IN CATEGORY" strategy, we are excited to be
introducing this new over-the-counter (OTC) ointment on a breathable
cloth patch product to be used for the temporary relief of pain and
itching associated with cold sores or fever blisters. The product is
designed to be applied at the first sign of a developing cold sore or
fever blister. TheraPatch Cold Sore covers the cold sore; it is easy
to use and eliminates the inconvenience of messy creams and gels.
With over 40 million people in the U. S. suffering from cold sores
or fever blisters, TheraPatch Cold Sore is uniquely positioned to
compete in the rapidly growing OTC lip therapy market segment. This
nearly $300 million dollar market has an attractive annual growth rate
of 11.7%.(a) TheraPatch Cold Sore is latex free and contains proven,
safe and effective ingredients to relieve the pain and itching, as
well as soothe and moisturize the affected lip area. "Results from our
consumer research indicate a strong acceptance of our new cold sore
product," commented Rodney A. Young, Chairman, CEO and President of
LecTec Corporation. "I am pleased to report that we have already
received orders and commitments from several major retailers during
our pre-market introduction," continued Young.
(a) Source: AC Nielsen 52 weeks ending 7/15/00
With this newest product, a total of ten TheraPatch products will
be available nationwide at food, drug and mass retailers. The
TheraPatch family of products currently available includes: TheraPatch
Cool and TheraPatch Warm, which provide temporary relief from minor
aches and pains; TheraPatch Anti-Itch "For Kids" and TheraPatch
Anti-Itch "Outdoors," which provide temporary relief from the itching
and pain associated with insect bites, minor skin irritations, and
rashes due to poison ivy/oak/sumac; and TheraPatch Vapor Chest,
TheraPatch Vapor Nose & Chin and TheraPatch Vapor Cherry Patch "For
Kids," which provide temporary relief from coughs due to colds, and
TheraPatch Headache and TheraPatch Fever "Cooling comfort patches",
which are non drug adjuncts to oral headache and fever medication.
"The introduction of TheraPatch Cold Sore once again demonstrates
LecTec's rapid innovation, speed to market capabilities and the
multiple applications of our patented ointment on breathable cloth
hydrogel/patch technology. We believe Cold Sore is another significant
innovation from our flourishing new product pipeline," concluded
Young.
LecTec is a health care and consumer products company that
develops, manufactures and markets products based on its advanced skin
interface technologies. Primary products include over-the-counter
topical drug delivery patch products.
This press release contains forward-looking statements that may
include statements regarding intent, belief or current expectations of
the company and its management. These forward-looking statements are
not guarantees of future performance and involve a number of risks and
uncertainties that may cause the Company's actual results to differ
materially from the results discussed in these statements. Factors
that might cause such differences include, but are not limited to,
buying patterns of major customers, market acceptance of LecTec's
products, competitive products, impact of interruptions to production,
availability of capital to finance growth, regulatory risks and other
risks and uncertainties detailed from time to time in the Company's
filings with the Securities and Exchange Commission.
CONTACT:
LecTec Corporation, Minnetonka
Rodney A. Young
or
Timothy R. J. Quinn
952/933-2291
Original article: http://www.businesswire.com/webbox/bw.121400/203492166.htm
